Skip to main content
. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077

Figure 2. Comparison of BAFF levels in controls and patients with MuSK.

Figure 2

(A) ELISA performed on plasma samples shows higher B cell–activating factor (BAFF) levels in patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis(MG) (p = 0.025). (B) Representative flow cytometry plots depict the surface expression of BAFF receptors (BAFF-R) on CD19+ cells, which was similar in healthy controls and patients with MuSK. Cells are gated on viable lymphocytes. (C, D) Log-transformed data of BAFF concentration (conc.) and MG manual muscle testing (MG-MMT) scores and BAFF concentration and disease duration (p = 0.008).